Pharmacokinetic Research Unit, Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, 65000, Thailand.
Center of Excellence for Environmental Health and Toxicology, Naresuan University, Phitsanulok, Thailand.
Eur J Drug Metab Pharmacokinet. 2022 Jan;47(1):105-116. doi: 10.1007/s13318-021-00735-8. Epub 2021 Nov 24.
Tacrolimus is a narrow therapeutic index drug with high pharmacokinetic variability, and several tacrolimus population pharmacokinetic (PopPK) models were developed to guide individualized drug dosing. These models, however, may not perform well in other clinical settings. Therefore, we aimed to assess the predictive ability of published tacrolimus PopPK models using a dataset of Thai kidney transplant patients.
The external dataset was retrospectively collected from medical records of Bhumibol Adulyadej Hospital, Thailand. Published tacrolimus PopPK models were systematically searched from PubMed, Science Direct, CINAHL Complete, and Scopus databases. Models conducted using a nonlinear mixed-effects approach with covariate resemblance to our external dataset were selected. The external dataset consisted of Thai kidney transplant patients receiving oral immediate- or extended-release tacrolimus formulations twice or once daily, respectively. Accuracy and precision of predicted concentrations were evaluated using mean absolute prediction error (MAPE), root mean square error (RMSE), and goodness of fit plots.
Only three models produced acceptable population predictions with the MAPE of < 50%. By using the Bayesian posthoc estimate of individual pharmacokinetic parameters, all models well performed with the MAPE and RMSE of < 30% and 40%, respectively, except two models; one could not successfully converge and the other substantially underpredicted tacrolimus concentrations.
We evaluated ten tacrolimus PopPK models, and eight models resulted in satisfactorily individual predicted tacrolimus concentrations in Thai kidney transplant patients and may be used to aid tacrolimus dose adjustment along with a clinical judgment.
他克莫司是一种治疗指数较窄、药代动力学变异性较高的药物,已开发出多种他克莫司群体药代动力学(PopPK)模型以指导个体化给药。然而,这些模型在其他临床环境中的表现可能并不理想。因此,我们旨在使用泰国肾移植患者的数据集评估已发表的他克莫司 PopPK 模型的预测能力。
从泰国曼谷玛希隆大学医院的病历中回顾性收集外部数据集。从 PubMed、Science Direct、CINAHL Complete 和 Scopus 数据库系统地搜索已发表的他克莫司 PopPK 模型。选择与我们的外部数据集具有相似协变量的非线性混合效应方法进行的模型。外部数据集包括接受口服即时或延长释放他克莫司制剂的泰国肾移植患者,分别每日两次或一次给药。通过平均绝对预测误差(MAPE)、均方根误差(RMSE)和拟合度图评估预测浓度的准确性和精密度。
只有三个模型的预测人群具有可接受的 MAPE < 50%。通过使用个体药代动力学参数的贝叶斯后验估计,所有模型的 MAPE 和 RMSE 均<30%和 40%,除了两个模型;一个模型无法成功收敛,另一个模型则显著低估了他克莫司的浓度。
我们评估了十个他克莫司 PopPK 模型,其中八个模型在泰国肾移植患者中产生了令人满意的个体化预测他克莫司浓度,并且可能与临床判断一起用于辅助他克莫司剂量调整。